Background: Aging, obesity, and diabetes favor vascular dysfunction. Endothelial activation of adenosine monophosphate-activated protein kinase (AMPK) has protective effects in diabetes. Methods: Mice with constitutive endothelial activation of AMPK (CA-AMPK) were given a high fat diet to induce obesity or kept on standard chow as lean controls for up to 2 years. A subset of obese animals was changed to standard chow after 30 weeks of high fat feeding. En-dothelium-dependent and endothelium-independent responses were examined by isometric tension recording. Results and Conclusion: Endothelium-dependent nitric oxide (NO)- and apamin plus charybdotoxin-sensitive relaxations were preserved and similar between aortic or renal arterial preparations of lean and obese CA-AMPK mice and their wild-type littermates. Despite comparable release of vasoconstrictor prostanoids, cyclooxygenase-dependent contractions were enhanced during NO synthase inhibition in carotid arterial rings of obese CA-AMPK mice. Contractions to the α1-adrenoceptor agonist phenylephrine were augmented in renal arteries of obese animals, a genotype-independent phenomenon reversible by weight loss. These data indicate a higher α1-adrenergic reactivity in renal arteries of aged mice with obesity. The current results highlight the potential of weight loss to alleviate vascular dysfunction. However, endothelial activation of the AMPK pathway in obesity may not be sufficient to prevent vascular dysfunction without lifestyle changes.

Keywords:
Acetylcholine, Adenosine monophosphate-activated protein kinase, EDCF, Endothelium, Endothelium-dependent hyperpolarization, Lifestyle, Phenylephrine, Thromboxane receptors
1.
Hubert HB, Feinleib M, McNamara PM, Castelli WP: Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham heart study. Circulation 1983; 67: 968–977.
2.
Brunner EJ, Shipley MJ, Ahmadi-Abhari S, Tabak AG, McEniery CM, Wilkinson IB, Marmot MG, Singh-Manoux A, Kivimaki M: Adiposity, obesity, and arterial aging: longitudinal study of aortic stiffness in the Whitehall II cohort. Hypertension 2015; 66: 294–300.
3.
Baretella O, Chung SK, Xu A, Vanhoutte PM: Endothelial overexpression of endothelin-1 modulates aortic, carotid, iliac and renal arterial responses in obese mice. Acta Pharmacol Sin 2017; 38: 498–512.
4.
Farb MG, Tiwari S, Karki S, Ngo DT, Carmine B, Hess DT, Zuriaga MA, Walsh K, Fetterman JL, Hamburg NM, Vita JA, Apovian CM, Gokce N: Cyclooxygenase inhibition improves endothelial vasomotor dysfunction of visceral adipose arterioles in human obesity. Obesity 2014; 22: 349–355.
5.
Traupe T, Lang M, Goettsch W, Münter K, Morawietz H, Vetter W, Barton M: Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens 2002; 20: 2239–2245.
6.
Rowlatt C, Chesterman FC, Sheriff MU: Lifespan, age changes and tumour incidence in an ageing C57BL mouse colony. Lab Anim 1976; 10: 419–442.
7.
Koga T, Takata Y, Kobayashi K, Takishita S, Yamashita Y, Fujishima M: Age and hypertension promote endothelium-dependent contractions to acetylcholine in the aorta of the rat. Hypertension 1989; 14: 542–548.
8.
Fisslthaler B, Fleming I: Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ Res 2009; 105: 114–127.
9.
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167–1174.
10.
Wang Y, Huang Y, Lam KS, Li Y, Wong WT, Ye H, Lau CW, Vanhoutte PM, Xu A: Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. Cardiovasc Res 2009; 82: 484–492.
11.
Li FY, Lam KS, Tse HF, Chen C, Wang Y, Vanhoutte PM, Xu A: Endothelium-selective activation of AMP-activated protein kinase prevents diabetes mellitus-induced impairment in vascular function and reendothelialization via induction of heme oxygenase-1 in mice. Circulation 2012; 126: 1267–1277.
12.
Lesniewski LA, Zigler MC, Durrant JR, Donato AJ, Seals DR: Sustained activation of AMPK ameliorates age-associated vascular endothelial dysfunction via a nitric oxide-independent mechanism. Mech Ageing Dev 2012; 133: 368–371.
13.
Krege JH, Hodgin JB, Hagaman JR, Smithies O: A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 1995; 25: 1111–1115.
14.
Baretella O, Xu A, Vanhoutte PM: Acidosis prevents and alkalosis augments endothelium-dependent contractions in mouse arteries. Pflugers Arch 2014; 466: 295–305.
15.
Gendron ME, Thorin-Trescases N, Villeneuve L, Thorin E: Aging associated with mild dyslipidemia reveals that COX-2 preserves dilation despite endothelial dysfunction. Am J Physiol Heart Circ Physiol 2007; 292:H451–H458.
16.
Tang EH, Ku DD, Tipoe GL, Félétou M, Man RY, Vanhoutte PM: Endothelium-dependent contractions occur in the aorta of wild-type and COX2–/– knockout but not COX1–/– knockout mice. J Cardiovasc Pharmacol 2005; 46: 761–765.
17.
Zhou Y, Varadharaj S, Zhao X, Parinandi N, Flavahan NA, Zweier JL: Acetylcholine caus es endothelium-dependent contraction of mouse arteries. Am J Physiol Heart Circ Physiol 2005; 289:H1027–H1032.
18.
Baretella O, Chung SK, Barton M, Xu A, Vanhoutte PM: Obesity and heterozygous endothelial overexpression of prepro-endothelin-1 modulate responsiveness of mouse main and segmental renal arteries to vasoconstrictor agents. Life Sci 2014; 118: 206–212.
19.
Auch-Schwelk W, Katusic ZS, Vanhoutte PM: Nitric oxide inactivates endothelium-derived contracting factor in the rat aorta. Hypertension 1992; 19: 442–445.
20.
Tang EH, Félétou M, Huang Y, Man RY, Vanhoutte PM: Acetylcholine and sodium ni troprusside cause long-term inhibition of EDCF-mediated contractions. Am J Physiol Heart Circ Physiol 2005; 289:H2434–H2440.
21.
Hanasaki K, Nakano K, Kasai H, Kurihara H, Arita H: Identification of thromboxane A2 receptor in cultured vascular endothelial cells of rat aorta. Biochem Biophys Res Commun 1988; 151: 1352–1357.
22.
Sung CP, Arleth AJ, Berkowitz BA: Endothelial thromboxane receptors: biochemical characterization and functional implications. Biochem Biophys Res Commun 1989; 158: 326–333.
23.
Edwards G, Dora KA, Gardener MJ, Garland CJ, Weston AH: K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998; 396: 269–272.
24.
Gluais P, Lonchampt M, Morrow JD, Vanhoutte PM, Félétou M: Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin. Br J Pharmacol 2005; 146: 834–845.
25.
Lüscher TF, Vanhoutte PM: Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986; 8: 344–348.
26.
Barton M, Carmona R, Morawietz H, d’Uscio LV, Goettsch W, Hillen H, Haudenschild CC, Krieger JE, Münter K, Lattmann T, Lüscher TF, Shaw S: Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension 2000; 35: 329–336.
27.
Belin de Chantemèle EJ, Mintz JD, Rainey WE, Stepp DW: Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. Hypertension 2011; 58: 271–279.
28.
Vanhoutte PM, Zhao Y, Xu A, Leung SW: Thirty years of saying NO: sources, fate, actions, and misfortunes of the endothelium-derived vasodilator mediator. Circ Res 2016; 119: 375–396.
29.
Mundy AL, Haas E, Bhattacharya I, Widmer CC, Kretz M, Baumann K, Barton M: Endothelin stimulates vascular hydroxyl radical formation: effect of obesity. Am J Physiol Regul Integr Comp Physiol 2007; 293:R2218–R2224.
30.
Liang CF, Liu JT, Wang Y, Xu A, Vanhoutte PM: Toll-like receptor 4 mutation protects obese mice against endothelial dysfunction by decreasing NADPH oxidase isoforms 1 and 4. Arterioscler Thromb Vasc Biol 2013; 33: 777–784.
31.
Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A: Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 2008; 114: 361–374.
32.
Xu A, Vanhoutte PM: Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am J Physiol Heart Circ Physiol 2012; 302:H1231–H1240.
33.
Davis BJ, Xie Z, Viollet B, Zou MH: Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006; 55: 496–505.
34.
Enkhjargal B, Godo S, Sawada A, Suvd N, Saito H, Noda K, Satoh K, Shimokawa H: Endothelial AMPK-activated protein kinase regulates blood pressure and coronary flow responses through hyperpolarization mechanism in mice. Arterioscler Thromb Vasc Biol 2014; 34: 1505–1513.
35.
Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I, Busse R: Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 1996; 94: 3341–3347.
36.
Najibi S, Cowan CL, Palacino JJ, Cohen RA: Enhanced role of potassium channels in relaxations to acetylcholine in hypercholesterolemic rabbit carotid artery. Am J Physiol 1994; 266:H2061–H2067.
37.
Olmos L, Mombouli JV, Illiano S, Vanhoutte PM: cGMP mediates the desensitization to bradykinin in isolated canine coronary arteries. Am J Physiol 1995; 268:H865–H870.
38.
Matsumoto T, Noguchi E, Ishida K, Kobaya-shi T, Yamada N, Kamata K: Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes. Am J Physiol Heart Circ Physiol 2008; 295:H1165–H1176.
39.
Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, Peggie MW, Zibrova D, Green KA, Mustard KJ, Kemp BE, Sakamoto K, Steinberg GR, Hardie DG: The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012; 336: 918–922.
40.
Rapoport RM, Williams SP: Role of prostaglandins in acetylcholine-induced contraction of aorta from spontaneously hypertensive and Wistar-Kyoto rats. Hypertension 1996; 28: 64–75.
41.
Baretella O, Vanhoutte PM: Endothelium-dependent contractions: prostacyclin and endothelin-1, partners in crime? Adv Pharmacol 2016; 77: 177–208.
42.
Liang Y, Huang B, Song E, Bai B, Wang Y: Constitutive activation of AMPK α1 in vascular endothelium promotes high-fat diet-induced fatty liver injury: role of COX-2 induction. Br J Pharmacol 2014; 171: 498–508.
43.
Grassi G, Mark A, Esler M: The sympathetic nervous system alterations in human hypertension. Circ Res 2015; 116: 976–990.
44.
Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME: Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 2015; 116: 991–1006.
45.
Barton M, Haudenschild CC, d’Uscio LV, Shaw S, Münter K, Lüscher TF: Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1998; 95: 14367–14372.
46.
Miller JD, Chu Y, Castaneda LE, Serrano KM, Brooks RM, Heistad DD: Vascular function during prolonged progression and regression of atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2013; 33: 459–465.
47.
Wycherley TP, Brinkworth GD, Keogh JB, Noakes M, Buckley JD, Clifton PM: Long-term effects of weight loss with a very low carbohydrate and low fat diet on vascular function in overweight and obese patients. J Intern Med 2010; 267: 452–461.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.